Please assess the completion status of the following clinical trial:

Trial Title: Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese, defined as BMI ≥ 30 kg/m2, at both time of abdominal fat imaging and at study entry.~* Ages 30-65~* No prevalent diagnosis of type 2 diabetes mellitus, either at the time of abdominal fat imaging or at study entry.~* Previous abdominal fat quantification by magnetic resonance imaging in the Dallas Heart Study or possible neck-to-knee MRI for VAT measurement may be performed.~Exclusion Criteria:~* Pregnant or breastfeeding~* Incarcerated~* Chronic kidney or liver disease~* History of frequent (\>2/year) urinary tract infections~* Non-obese either at time of abdominal fat imaging or at present.~* Greater than 10% change in body weight (kg) between time of abdominal fat imaging and present.~* Has donated blood within last 6 weeks~* Cannot give informed consent, understand the protocol, or tolerate any aspect of the protocol~* If undergoing MRI, persons with metal implants contraindicated for 3Tesla MRI exams will be excluded. Severe claustrophobia will also be assessed prior to an MRI exam.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): Empagliflozin 10 mg by mouth daily for 3 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo one tablet daily for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).